Skip to main content

Table 2 Five-year survival rates of the 730 NPC patients

From: The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis

 All
(N = 730)
Nimotuzumab Arm
(N = 184)
No Nimotuzumab Arm
(N = 546)
Chi-squareP value
DMFS87.49%93.09%85.61%6.3430.012
 III89.81%94.59%88.22%  
 IV83.43%90.56%80.93%  
LRRFS88.60%85.34%89.79%2.0120.156
 III90.16%87.22%91.21%  
 IV85.71%82.00%87.17%  
PFS78.47%79.96%77.99%2.4590.117
 III78.72%81.27%77.88%  
 IV63.15%70.90%60.52%  
OS80.96%88.91%78.30%7.5650.006
 III88.53%96.33%85.97%  
 IV67.69%76.24%64.79%  
  1. OS overall survival, DMFS distant metastasis–free survival, LRRFS locoregional relapse–free survival, and PFS progression-free survival